BioCardia, Inc. Stock price

Equities

BCDA

US09060U5074

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-18 pm EDT 5-day change 1st Jan Change
0.3863 USD -0.95% Intraday chart for BioCardia, Inc. -8.35% -41.84%
Sales 2023 * 700K Sales 2024 * 700K Capitalization 10.01M
Net income 2023 * -13M Net income 2024 * -15M EV / Sales 2023 * 14.3 x
Net cash position 2023 * - Net cash position 2024 * - EV / Sales 2024 * 14.3 x
P/E ratio 2023 *
-0.84 x
P/E ratio 2024 *
-0.92 x
Employees 33
Yield 2023 *
-
Yield 2024 *
-
Free-Float 58.27%
More Fundamentals * Assessed data
Dynamic Chart
BioCardia, Inc. and StemCardia, Inc. Announce Long-Term Partnership to Advance StemCardia?s Investigational Pluripotent Stem Cell Product Candidate for Treatment of Heart Failure CI
BioCardiaAnnounces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study CI
Biocardia Reports Positive Interim Results from Phase III Cardiamp Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure CI
BioCardia, Inc. announced that it expects to receive $0.874999 million in funding CI
BioCardia, Inc.  Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA CI
BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction CI
BioCardia, Inc. Announces Expected Cardiamp Heart Failure Japan Approval Based on Pharmaceutical and Medical Device Agency Consultation Minutes CI
BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure CI
Sector Update: Health Care Stocks Slightly Advancing Late Afternoon MT
Sector Update: Health Care MT
BioCardia to Sell $1.3 Million Shares to Healthcare Investor; Shares Fall MT
Sector Update: Health Care Stocks Higher Late Afternoon MT
Top Midday Gainers MT
Sector Update: Health Care Stocks Advancing in Afternoon Trading MT
Sector Update: Health Care MT
More news
1 day-0.95%
1 week-8.35%
Current month-29.76%
1 month-13.96%
3 months-40.66%
6 months+3.29%
Current year-41.84%
More quotes
1 week
0.39
Extreme 0.3863
0.42
1 month
0.37
Extreme 0.3709
0.59
Current year
0.37
Extreme 0.3709
0.72
1 year
0.36
Extreme 0.36
2.92
3 years
0.36
Extreme 0.36
5.10
5 years
0.00
Extreme 0
17.50
10 years
0.00
Extreme 0
138.24
More quotes
Managers TitleAgeSince
Chief Executive Officer 57 01-12-31
Director of Finance/CFO 61 13-08-31
Chief Tech/Sci/R&D Officer - 17-07-31
Members of the board TitleAgeSince
Director/Board Member 88 01-12-31
Director/Board Member 70 10-12-31
Director/Board Member 82 16-10-23
More insiders
Date Price Change Volume
24-03-18 0.3863 -0.95% 118,686
24-03-15 0.39 -0.86% 155,697
24-03-14 0.3934 +1.03% 295,080
24-03-13 0.3894 +2.07% 810,107
24-03-12 0.3815 -9.49% 4,614,325

Delayed Quote Nasdaq, March 18, 2024 at 04:30 pm EDT

More quotes
BioCardia, Inc. is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. It is advancing two cell therapy platforms derived from bone marrow such as CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI); and neurokinin-1 receptor positive (NK1R+) allogeneic mesenchymal stem cell (MSC) therapy platform is being advanced for two clinical indications: the treatment of ischemic HFrEF and acute respiratory distress syndrome (ARDS). Its autologous CardiAMP and allogeneic NK1R+ cell therapies intended for cardiac indications of HFrEF and CMI are enabled by its Helix minimally invasive intramyocardial therapeutic delivery platform. Helix delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.3863 USD
Average target price
4 USD
Spread / Average Target
+935.46%
Consensus
  1. Stock
  2. Equities
  3. Stock BioCardia, Inc. - Nasdaq